20 Aug Date August 20, 2025 Author TelaraPharma Tags Dr. Alberto Lázaro, The Cilastatin project New paper published: Cilastatin Modulates DPEP1- and IQGAP1-Associated Neuro-Glio-Vascular Inflammation in Oxaliplatin-Induced Peripheral Neurotoxicity Martín-Ramírez R, González-Nicolás MÁ, Álvarez-Tosco K, Machín F, Ávila J, Morales M, Lázaro A, Martín-Vasallo P.Cells....
16 Aug Date August 16, 2025 Author TelaraPharma Tags Arch Biopartners, Dr. Alberto Lázaro, The Cilastatin project New paper published: Cilastatin Attenuates Acute Kidney Injury and Reduces Mortality in a Rat Model of Sepsis. https://www.mdpi.com/1422-0067/26/16/7927 González-Nicolás MÁ, Humanes B, Herrero R, Arenillas M, López B, Ferruelo A, Lore...
24 Jul Date July 24, 2025 Author TelaraPharma Tags Arch Biopartners, renal injury, The Cilastatin project Arch Biopartners Announces Start of Patient Recruitment in Phase II PONTIAK Trial Targeting Drug-Toxin-Related Acute Kidney Injury (AKI) We at Telara Pharma are thrilled to see our partner Arch Biopartners Inc (ARCH:TSXV) (ACHFF:OTCQB) announce the start of patient r...
30 Jun Date June 30, 2025 Author TelaraPharma DESARROLLO DE UN NUEVO AGENTE PROTECTOR DE LA APOPTOSIS, LA CILASTATINA, DIRIGIDO AL TRATAMIENTO DE PROCESOS NEURODEGENERATIVOS ...
27 May Date May 27, 2025 Author TelaraPharma Tags Dr. Alberto Lázaro, Gregorio Marañon, The Cilastatin project Telara Pharma Earns Emerging Company Certification from Enisa Telara Pharma is proud to announce that it has been officially recognized with the Emerging Company Certification, granted by the...